A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours

NCT06868199 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumours

Interventions

DRUG: LM-168
DRUG: Toripalimab

Sponsor

LaNova Medicines Limited